Canadian researchers comparing Retatrutide vs Tirzepatide in Canada face a clear choice between a dual agonist and a triple agonist. Both compounds are available at Boreals Peptides in pen and vial format with Canada Post Xpresspost delivery. This guide explains the science, the clinical data and which is right for Canadian research.
Tirzepatide targets two hormone receptors: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual agonism made Tirzepatide the most advanced GLP-1 compound when it was introduced in clinical research. Retatrutide adds a third receptor — glucagon — to the mechanism, making it a triple agonist targeting GLP-1, GIP and glucagon simultaneously. The glucagon receptor is responsible for energy expenditure pathways not addressed by GLP-1/GIP alone. This additional mechanism is believed to be the primary reason Retatrutide outperforms Tirzepatide in clinical trial data.
Phase 2 Tirzepatide data showed approximately 20.9% results at the highest dose over 72 weeks in separate trials. Phase 2 Retatrutide data showed 24.2% average results at the highest dose over 48 weeks — a meaningful difference in a shorter trial period. The Phase 3 TRIUMPH program for Retatrutide is ongoing with results expected 2026. Canadian researchers studying these compounds consistently note that Retatrutide's Phase 2 data represents the largest clinical trial results ever observed for a weight management compound.
Boreals Peptides stocks both Retatrutide and Tirzepatide for Canadian researchers. Retatrutide is available in pen format (Synedica 40mg pen CA$234.99) and vial format (10mg CA$149.99, 20mg CA$189.99, 40mg CA$219.99). Tirzepatide (Mounjaro) covers all doses from 2.5mg (CA$169.99) to 15mg (CA$499.99) plus the 40mg injection pen kit (CA$179.99). Both ship via Canada Post Xpresspost to all Canadian provinces. Free over CA$200.
Canadian researchers studying metabolic health, weight management pathways or triple vs dual receptor agonism should consider Retatrutide as the more advanced compound based on current Phase 2 data. Canadian researchers with established Tirzepatide protocols, or those comparing GLP-1/GIP versus GLP-1/GIP/glucagon mechanisms, should stock both. Boreals Peptides makes this easy — both compounds are in stock with Canada Post Xpresspost delivery and free shipping over CA$200.
One of Boreals Peptides' key advantages is pen format availability for both compounds. The Retatrutide Synedica 40mg pen and the Tirzepatide 40mg injection pen kit both eliminate reconstitution requirements for Canadian researchers. No bacteriostatic water, no separate syringes. Simply attach a needle and the pen is research-ready. Boreals Peptides is one of the only Canadian suppliers offering pen format for both Retatrutide and Tirzepatide.
All Boreals Peptides Retatrutide and Tirzepatide orders ship via Canada Post Xpresspost. Interac e-Transfer accepted on all orders. Bitcoin orders receive 10% off — making Retatrutide 10mg CA$134.99 and Tirzepatide 40mg pen kit CA$161.99 with Bitcoin. Free Xpresspost over CA$200. Ontario and BC in 1–2 days. All provinces in 1–3 business days.
